CLINICAL TRIALS PROFILE FOR TERAZOSIN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Terazosin Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | US Department of Veterans Affairs | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00007592 ↗ | Hypertension Screening and Treatment Program | Completed | VA Office of Research and Development | 1989-06-01 | Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension. | |
| NCT00201630 ↗ | Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy | Unknown status | Sanofi | Phase 3 | 2005-09-01 | To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or not than starting it on the day of surgery. |
| NCT00201630 ↗ | Prophylactic Vs. Therapeutic Use of Uroxatrol in Men Undergoing Brachytherapy | Unknown status | New York Prostate Institute | Phase 3 | 2005-09-01 | To asess the efficacy of Uroxatrol, an alpha blocker in men undergoing prostate brachytherapy to treat prostate cancer, and whether the use of Uroxatrol in advance of the brachytherapy is better or not than starting it on the day of surgery. |
| NCT00237510 ↗ | Pilot Study of Terazosin in Treatment of Antidepressant Induced Excessive Sweating | Completed | Thomas Jefferson University | N/A | 2005-05-01 | This study is based on the hypothesis that terazosin, a blocker of alpha-1 receptors, will be effective in reducing excessive sweating caused by antidepressant treatment, and will have minimal adverse effects. |
| NCT00381108 ↗ | Study of the Effects of Pomegranate Tablets on Enlarged Prostates | Unknown status | Jarrow Pharmaceuticals | Phase 1 | 2005-09-01 | To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia. |
| NCT00381108 ↗ | Study of the Effects of Pomegranate Tablets on Enlarged Prostates | Unknown status | Pomegranate Health | Phase 1 | 2005-09-01 | To determine whether pomegranate tablets have a therapeutic effect on Benign Prostatic Hyperplasia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Terazosin Hydrochloride
Condition Name
Clinical Trial Locations for Terazosin Hydrochloride
Trials by Country
Clinical Trial Progress for Terazosin Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Terazosin Hydrochloride
Sponsor Name
